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Abstract: 
Cancer is a disease of aging.
1 Currently 50% of all malignancies occur in 
over
1 and by the year 2030 older individuals will account for 70% of all neoplasms. 
With  the  aging  of  the  population  the  management  of  cancer  in  the  older  person  with 
chemotherapy is beoming increasingly common. This treatment may be  s
some appropriate measures are taken, including, an assessment of the physiologic age of each 
patient, modification of doses according to the renal function, use of meyelopoietic growth 
factors prophylactically in presence of moderately
adequate  caregiver.  Cure,  prolongation  of  survival,  and  symptom  palliation  are  universa
goals  of  medical treatment.  Prolongation  of active  life expectancy should be  added to  the 
treatment goal of the older aged per
Introduction: The  management  of  cancer  in  the 
older  aged  person  is  an  increasingly  common 
problem.  Cancer is a disease of aging.
50% of all malignancies occur in individuals 65 and 
over
1  and by the year 2030 older individuals will 
account for 70% of all neoplasms. 
The  management  of  cancer  in  the  older
person include some questions that are specfic of 
aging:
 Is  the  person  life  expectancy  going  to  be 
shortened by cancer?
 Is the patient’s life expectancy long enough 
that he or she will experience the complications of 
cancer?
 Is the patient able to tolerate antineoplastic 
treatment?
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Currently 50% of all malignancies occur in individuals 65 and 
and by the year 2030 older individuals will account for 70% of all neoplasms. 
With  the  aging  of  the  population  the  management  of  cancer  in  the  older  person  with 
chemotherapy is beoming increasingly common. This treatment may be  safe and effective if 
some appropriate measures are taken, including, an assessment of the physiologic age of each 
patient, modification of doses according to the renal function, use of meyelopoietic growth 
factors prophylactically in presence of moderately toxic chemotherapy, and provision of an 
adequate  caregiver.  Cure,  prolongation  of  survival,  and  symptom  palliation  are  universa
Prolongation  of active  life expectancy should be  added to  the 
treatment goal of the older aged person.
The  management  of  cancer  in  the 
older  aged  person  is  an  increasingly  common 
problem.  Cancer is a disease of aging.
1 Currently 
occur in individuals 65 and 
and by the year 2030 older individuals will 
The  management  of  cancer  in  the  older-aged 
person include some  questions  that are specfic  of 
Is the  person  life  expectancy  going  to  be 
Is the patient’s life expectancy long enough 
that he or she will experience the complications of 
Is the patient able to tolerate antineoplastic 
 What  are  the  long  term  side  effects  of 
cancer treatment in the older person?
 Does  the  patient  have  adequate  social 
support to undergo cancer treatment? 
We will address these questions using cytotoxic 
chemotherapy  as  a  model.  After  an  overview  of 
aging  and  its  assessment  we  will  explore  the 
pharmacologic changes of aging and t
to ameliorate the complications of chemotherapy.
Age and its assessment: Aging implies a decline in 
life expectancy and stress-coping ability,  increased 
prevalence of  comorbidity,  increased  risk
functional dependence  and of  the need of social 
support.
2 Though  it  is  universal,  aging  is  highly 
individualized  and  is  poorly  reflected  in 
chronologic  age.  The  management  of    the  older
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individuals 65 and 
and by the year 2030 older individuals will account for 70% of all neoplasms. 
With  the  aging  of  the  population  the  management  of  cancer  in  the  older  person  with 
afe and effective if 
some appropriate measures are taken, including, an assessment of the physiologic age of each 
patient, modification of doses according to the renal function, use of meyelopoietic growth 
toxic chemotherapy, and provision of an 
adequate  caregiver.  Cure,  prolongation  of  survival,  and  symptom  palliation  are  universal 
Prolongation  of active  life expectancy should be added to the 
What  are  the  long  term  side  effects  of 
son?
Does  the  patient  have  adequate  social 
support to undergo cancer treatment? 
We will address these questions using cytotoxic 
chemotherapy  as  a  model.  After  an  overview  of 
aging  and  its  assessment  we  will  explore  the 
pharmacologic changes of aging and the provisions 
to ameliorate the complications of chemotherapy.
Aging implies a decline in 
coping ability,  increased 
of  comorbidity,  increased  risk of 
functional dependence  and of  the need of social 
Though  it  is  universal,  aging  is  highly 
individualized  and  is  poorly  reflected  in 
chronologic  age.  The  management  of    the  olderMedit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 1: Comprehensive Geriatric Assessment (CGA)                               
Domain Assessment
Function
Comorbidity
Presence of Geriatric Syndromes
Social support
Nutrition
Polypharmacy
 Performance Status (PS)
 Activities of Daily Living (ADL)
Continence, transferring, grooming, dressing, feeding, utilization of the bathroom.
 Instrumental Activities of daily living  (IADL)
Use of transportation, ability to take medications, to use the telephone, to go shopping, to 
take care of finances, to provide to one’s meals
 Advanced activities of daily living. 
These include all activities that make the patient’s life enjoyable.
 Number of comorbid conditions
 Comorbidity scales (assessing the seriousness of each condition)
 Dementia (cognitive evaluation)
 Depression (screening tests, such as the geriatric depression scale)
 Delirium 
 Falls (risk of falls assessment)
 Vertigo
 Spontaneous fractures
 Failure to thrive ( weigh loss in face of normal food intake)
 Neglect and abuse
 Living conditions
 Presence and reliability of the caregiver
 Economical resources
 Nutritional status
 Nutritional risk (typical meals, access to food, etc)
 Number of medications
 Risk of drug interactions
aged person should be based on an assessment of 
physiologic  rather   than chronologic age.
Aging has been defined as loss of entropy and 
fractality
3  and as  loss  of  homeostasis.
4 Entropy 
reflects the ability of a system  to produce and to 
waste  energy.  A fractal is a unit subdividing into 
subunits of the same type, but whose number and 
size  are unpredictable,  similar  to  the  branch  of  a 
tree.   The maintenance of life is trusted to structural 
and  dinamic  fractals.  In  the  mammalian  body 
structural  fractals  include  the  respiratory, 
circulatory  and  nervous  systems;  the  dinamic 
fractals include  the process of cell generation. For 
example, in hemopoiesis, few pluripotent stem cells 
give origin to a number of committed progenitors 
from  which  the  differentiated  precursors  of  the 
circulating  blood  cells  are  derived.  Commitment 
and  differentiation  involve  the  branching  of  the 
pluripotent stem cell into progressively larger cell 
populations.  Entropy  and  fractality  cannot  be 
directly assessed  by clinical means. The loss of cell 
replicating ability, expressed by a reduced length of 
leukocyte telomeres,
5 may be seen as an expression 
of the loss of fractality. A number of studies  have 
explored the possibility that the length of leukocyte 
telomeres  provide  a  reliable  assessment  of 
physiologic  age,  but  correlating  the  length  of 
telomeres  to  the  risk  of  functional  dependence, 
geriatric  syndromes,  and  other  manifestations  of 
age. The results so far have been inconclusive.
5-10
Homeostasis is the ability of a system to restore 
basic  conditions  after  stress  imposed  by 
environmental  interactions.  One  may  observe  the 
dysregulation  of  a  number  of  physiologic 
parameters,  including  blood  pressure,  insulin 
sensitivity,  circulating levels of corticosteroid and 
cathecolamines.  The  so  called  “allostatic  load” 
assesses  the  dysregulation  of  12  different 
parameters and  may estimate the physiologic age. 
Its  clinical  value  so  faris  unestablished.
4 Chronic 
and progressive inflammation is arguably the best 
recognized  manifestation  of  allostasis..  Aging  is 
associated  with  increased  concentration  of 
circulating  inflammatory  markers,  including 
inflammatory  cytokines  and  fibrinolytic  products. 
The concentration of  Interleuking 6, D-Dimer, and 
C-reactive protein is associated with increased risk 
of  death,  functional  dependence  and  geriatric 
syndromes
11-14 and may mirror the physiologic  age 
of the person.Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Inflammatory  markers  and    the  length  of 
leukocyte telomeres  are promising laboratory tests, 
but at present have limited clinical use.   
The  best  validated  instrument  for  the 
assessment  of  chronologic  age  is  the 
Comprehensive  Geriatric  Assessment”  (CGA), 
whose elements are illustrated in Table 1.
15-17
Dependence  in  one  or  more  ADLs  and  the 
presence of one or more geriatric syndromes imply 
a marginal  functional reserve  associated with  very 
limited  tolerance  of  stress.  These  individuals  can 
only survive thanks to  a full time home caregiver, 
or  to  admission  to  an  adult  living  facility.     
Dependence in one or more IADLs  is associated  
increased risk of mortality,
18-21 of dementia, and of 
chemotherapy-induced  toxicity.
20-21 These 
individuals need a caregiver to negotiate the outside 
world.
In  addition  to  reduced  life-expectancy  and  
increased  risk  of  treatment  complications
22-24
comorbidity  may be associated to changes in the 
natural history of cancer  and  polypharmacy. It is 
usefule  to  mention  that    diabetes  has  been 
associated  with  worsened  prognosis  of  most 
common  neoplasms including  cancer  of  the  large 
bowel, of the prostate and of the breast.
22,25 Anemia  
deserves a special mention as it is associated with 
increased  risk  of  overall  mortality  in  older 
individuals,  of  functional  dependence    and  of 
chemotherapy-induced  myelotoxicity.
26
Polypharmacy    may  be  responsible  of  iatrogenic 
morbidity  and  of  unfavorable  interactions  with  
antineoplastic  drugs.
27-28 In  addition,  drug 
interactions  are  a  major  cause  of  iatrogenic 
morbidity.
Some elements of the CGA may be utilized  in 
models  that  predict  the  mortality  and  the  risk  of 
chemotherapy-related  toxicity  in  older 
individuals.
20-21,29-31 In  addition,  the  CGA identify 
reversible  conditions that    interfere  with  cancer 
treatment,  including  comorbidity,  malnutrition, 
absence of a reliable caregiver.
32-34
Any  discussion  of  the  assessment  of 
physiologic  age  should  include  frailty.    This  is 
constructed  as  a  condition  of    critically  reduced 
physiologic  reserve  so  that  a  minimal  stress  may 
cause loss of independence  and start a  chain of 
events that lead to the patient ‘s death.
3
The  clinical  definition  of  frailty  was  first 
provided  by  the  Cardiovascular  Health  Study 
(CHS).
35 Eighty-five  hundred  individuals  65  and 
over  were  followed  for  an  average  of  11  years. 
Based  on  five  simple  parameters  they  could  be 
divided  into  three  groups    with  different  risk  of 
mortality, disability, and admission to adult living 
facilities. The parameters of interest included:
 Involuntary weight loss of 10 lbs or more 
over a 6 months period;
 Decreased grip strength;
 Difficulty in starting movements;
 Reduced walk speed;
 Exhaustion.
The three groups of individuals were classified 
as: non-frail or fit (no abnormalities); pre-frail (up 
to  two  abnormalities),  and  frail  (three  or  more 
abnormalities).
Another index of frailty validated both in older 
women and older men has been provided   by the 
Study  of  Osteoporotic  Fracture (SOF)
36  and  older 
men.
37 Based  on  the  performance  of  simple 
exercises (rising five times from a chair) it appears 
as accurate a predictor  of falls,  death, fractures and 
disability  as  the  CHS  instrument.  Canadian 
investigators developed a  frailty index
38 involving 
the  accumulation  of  40  functional  deficits.  This 
appears  too  time-consuming  for  clinical  practice. 
The  CHS  classification  represents  the  golden 
standard for ongoing studies of frailty. Fatigue was 
the  first  harbinger  of  frailty in  about 73%  of the 
cases  detected  in  the  CHS.
39 This  finding  is 
germane  to  our  discussion  as  fatigue  is  the  most 
common chronic manifestation of cancer.
The interactions of aging and frailty should be 
clarified. In particular we  should ask: is cancer a 
cause of frailty? Is chemotherapy a cause of frailty? 
Is  frailty  associated  with  increased  risk  of 
therapeutic complications?
Cytotoxic  chemotherapy:  Aging    is    associated 
with  pharmacokinetic  and  pharmacodinamic 
changes that    may    enhance  the  toxicity of  these 
agents (Table 2).
40
The most common pharmacokinetic changes of 
age  include  reduced  glomerular  filtration  rate, 
which prevents renal  excretion  of drugs and their 
metabolites, and reduced vD of hydrosoluble drugs,  
that  is  associated  with  increased  AUC  of  these 
agents. The Vd is influences by body composition, 
serum albumin  and hemoglobin  concentration.  Of 
these  only  the  hemoglobin  concentration  can  be 
modified  at  least  in  a  short  term.  As  discussed 
previously, anemia, is associated with increased risk 
of  chemotherapy-related  toxicity  because  several 
medications  are  bound  to  red  blood  cells.  In 
presence of anemia the concentration of fre drugs is 
increased. 
It  is  not  clear  at  present  whether  an  age-
associated  decline  in  food  absorption  affects  the Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 2. A pharmacokinetic changes of aging
Parameter Age-related change
Absorption and bioavailability Probably decreased
Volume of distribution (Vd)
Decreased for water-soluble agents --- increased plasmatic concentration
Increased for lipid-soluble agens
Metabolism Decreased hepatic metabolism
Excretion
Renal: decreased
Biliary: not affected
bio-availability of oral drugs. This issue need to be 
studies
Both the splanchnic circulation and the hepatic 
mass decrease with age. These changes conjure to 
reduce  drug  metabolism,  especially  when the 
cytochrome  P450  reactions  are  involved.  In 
addition,  polypharmacy  may  modulate  the 
cytochrome P450 system and inhibit or accelerate 
the metabolism of a number of drugs. The biliary 
excretion  appears  unaffected  by  age,  but  it  is 
important to remember that some drugs, including 
idarubicin,  daunorubicin,  and  morphine,  give 
origine to active and toxic metaboites eliminated by 
the kidneys. The toxicity of these agents may then 
be enhanced in the presencce of declining GFR.
Some complications of cytotoxic chemotherapy 
become more common with aging. 
The risk of neutropenia, neutropenic infections, 
and  infectious deaths  increase with the age of the 
patient.
41    Fortunately,  the  Granulocyte  Colony  
Stimualting  Factors  (G-CSF)  filgrastim, 
pegfilgrastim and lenograstim are effective in older 
individuals and reduce by more than 50% the risk of 
infections.
42-43 The  use  of  these    compounds  has 
been  associated  with  increased  risk  of 
myelodysplasia  and  acute  myeloid  leukemia  in 
older  individuals.
44 The  risk  of  thrombocytopenia 
and anemia also increase with age, albeit to a lesser 
extent.  These  complications  are  rarely  lethal  but 
may  cose  a  reduction  of  the    dose  intensity  of 
chemotherapy and  compromise the control of the 
tumor. Erythopoietic stimulating agents  reverse the 
majority of chemotherapy-related anemias, but the 
use of these compounds is currently limited out of 
concern for hypertension,  thrombosis and enhanced 
tumor growth.
45  
Mucositis,  whose  incidence  and    severity 
increase  with  age, causes dysphagia, diarrhea and 
rapid  volume  depletion  in  older  individuals.  
Aggressive fluid resuscitation should be initiated in 
patients unable to ingest fluids. The prevention of  
mucositis has limited effectiveness and may include 
solutions of glutamine,  supersaturated solutions of 
calcium  phosphate,  and  keratynocyte  growth 
factor.
4  Fatigue  is  a  feeling  of  exhaustion  not 
releived by rest and is the most common long term 
complication of  cancer  chemotherapy.
47-48 The 
pathogenesis  of  chemotherapy induced  fatigue   is 
poorly  understood,  Correction  of  anemia  may 
improve  fatigue  in  some  patients.  In  older 
individuals, fatigue is a a harbinger of frailty.
39
Age  is  also  a  risk  factor  for  anthracycline 
cardiomyopathy  and    for  peripheral  neuropathy.
40   
The risk of cardiomyopathy may be reduced by the 
administration  of  doxorubicin  as  a  continuous 
infusion,  by  the  concomitant  administration  of 
doxorubicin and the antidote desrazoxane, or by the 
use of pegylated liposomal doxorubicin “in lieu” of 
doxorubicin. None of these approaches is routinely 
used  in  older  individuals,  because  of  cost, 
alternative  toxicity  and  also  because  the  dose  of 
doxorubicin  employed  is  rarely  associated  with 
cardiotoxic complications. 
No antidote for peripheral neurotoxiciy exists. 
This complication may impair the independence of 
older  individuals by    impeding  both  walking  and 
fine hand movements. The only prevention consists 
in trying to avoid combination of neurotoxic drugs 
(example  cisplatin  and  paclitaxel)  and  in 
interrupting  treatment    when  the  neuropathy  may 
interfere with an individual’s activity.
An  important  and  unanswered  question  is 
whether  age is a risk factor for more frequent andMedit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 3. Common complications of cytotoxic chemotherapy
Universal complications Complications specific of certain agents
 Myelosuppression  Cardiotoxicity: anthracyclines
 Nausea and vomiting  Neurotoxicity (peripheral): alkaloids, taxanes, epothlilones, platinum 
derivatives
 Mucositis  Neurotoxicity (central): cytarabin in high doses, methotrexate in high 
doses; ifosphamide; gemcitabine
 Fatigue  Pulmonary fibrosis: bleomycin, methotrexate
 Renal insufficiency: cisplatin
more severe manifestations of “chemobrain” that is 
a cognitive dysfunction caused by chemotherapy.
Age is a risk factor for delayed complications of 
chemotherapy.  Myelodysplasia  and  acute  myeloid 
leukemia may develop in 1-2% of patients 65 and 
over  who  had  received  anthracycline-containing 
treatment in the previous 10 years. The risk of these 
complications is enhanced by myelopoietic growth 
factors.
44 The  incidence  of  a  chronic 
cardiomyopathy,  manifested  by  a  progressive 
decline  of  the  ejection  fraction,  is  seen  in 
approximately  19%  of  individuals  65  an  older  5 
years  or  longer  after  treatment  with  an 
anthracycline.
49
Other  potential  long  term  complications  of 
cancer  chemotherapy include  dementia,  functional 
dependence and frailty.
Treatment  goals: Cure,  prolongation  of  survival, 
and  symptom  palliation  are  universal  goals  of 
medical  treatment.      Prolongation  of  active  life 
expectancy  should be added to the treatment goal 
of the older aged person. 
  The  construct  of  active  life  expectancy
50 
include  preservation  of  functional  independence 
(that is ability to carry on ADLs and IADLs)  as 
well  as  preservation  of  the  ability  to  perform 
activities that are pleasearuble and fulfilling(the so-
called advanced activities of daily living). For this 
purpose it is important to obtain a so called” value 
history”  at  the  beginning  of  treatment    to  detect 
what are the patients main objectives in the lasting 
years  of  his/her  life  and  to  make  sure  that  the 
treatment is aimed to preserve these objectives.
   
Conclusions: With the aging of the population the 
management  of  cancer  in  the  older  person  with 
chemotherapy  is  beoming  increasingly  common. 
This treatment may be  safe and effective if some 
appropriate  measures  are  taken,  including,  an 
assessment of the physiologic age of each patient, 
modification  of  doses  according  to  the  renal 
function,  use  of  meyelopoietic  growth  factors 
prophylactically  in  presence  of  moderately  toxic 
chemotherapy,  and  provision  of  an  adequate 
caregiver.   The goals of treatment should include 
prolongation of active life-expectancy.
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